11/5
04:01 pm
rare
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Medium
Report
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
11/1
09:29 am
rare
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? [Yahoo! Finance]
Low
Report
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? [Yahoo! Finance]
10/29
04:05 pm
rare
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
Low
Report
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
10/23
11:56 am
rare
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year [Yahoo! Finance]
Low
Report
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year [Yahoo! Finance]
10/22
11:39 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
10/21
02:22 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $61.00 to $73.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $61.00 to $73.00. They now have a "buy" rating on the stock.
10/18
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/7
02:29 pm
rare
Ultragenyx gains Breakthrough Therapy status for setrusumab for genetic disorder Oct. 07, 2024 2:27 PM ET By: Jonathan Block , SA News Editor [Seeking Alpha]
Low
Report
Ultragenyx gains Breakthrough Therapy status for setrusumab for genetic disorder Oct. 07, 2024 2:27 PM ET By: Jonathan Block , SA News Editor [Seeking Alpha]
10/7
08:00 am
rare
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
Low
Report
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
10/3
04:30 pm
rare
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Low
Report
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
10/1
09:12 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
9/26
10:15 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
9/26
08:00 am
rare
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
Low
Report
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
9/18
05:00 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/16
01:06 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
9/5
01:24 am
rare
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now [Yahoo! Finance]
Low
Report
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now [Yahoo! Finance]
8/29
04:30 pm
rare
Ultragenyx to Participate in Investor Conferences in September
Low
Report
Ultragenyx to Participate in Investor Conferences in September
8/22
10:41 am
rare
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective [Seeking Alpha]
Low
Report
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective [Seeking Alpha]
8/21
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)